NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で22.93%の成長率を示しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 727.33Mです。
適正水準
同社の最新のPEは-19.39で、過去3年間の水準と比較して適正圏にあります。
機関投資家の買い増し
最新の機関投資家の保有株数は156.61M株で、前四半期比で4.58%増加しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は0.79です。